Journal: iScience

Article Title: The STING1-MYD88 complex drives ACOD1/IRG1 expression and function in lethal innate immunity

doi: 10.1016/j.isci.2022.104561

Figure Lengend Snippet:

Article Snippet: Concentrations of proteins in the supernatant were determined by a BCA Protein Assay Kit (7780, Cell Signaling Technology).

Techniques: Recombinant, Control, Lysis, Enzyme-linked Immunosorbent Assay, cDNA Synthesis, Bicinchoninic Acid Protein Assay, Magnetic Beads, Chromatin Immunoprecipitation, Purification, CCK-8 Assay, shRNA, Software, Western Blot

Journal: bioRxiv

Article Title: Tertiary lymphoid structures induced by CXCL13-producing CD4 + T cells increase tumor infiltrating CD8 + T cells and B cells in ovarian cancer

doi: 10.1101/2021.12.01.470493

Figure Lengend Snippet: (A) Representative TLS in tissues stained by H&E and CXCL13 (Fast RED) by RNA ISH. Scale bars indicate 100 µm. (B) TLS presence ratio based on CXCL13 gene expression. Analysis by Fisher’s exact test in 28 cases with microarray data. (C) Characterization of the immune infiltrate in tumors according to CXCL13 gene expression (n=28). Correlation was determined by Spearman’s correlation test. (D) (E) The distribution of infiltrating immune cells into the tumor site and CXCL13 gene expression using CIBERSORT (n=522). Correlation was determined by Spearman’s correlation test. (F) Overall survival of patients with HGSC by CXCL13 gene expression (TCGA n=217, KOV n=28). Patients with CXCL13 high defined if CXCL13 gene expression was above the median. Analyses were performed with Kaplan-Meier estimates, log-rank tests and Wilcoxon tests. The level of significance was set as * P <0.05, ** P <0.01, and **** P <0.0001.

Article Snippet: Mouse recombinant CXCL13 (R&D Systems) treatment was initiated one day after the tumor inoculation and administered intraperitoneally at 1 μg/mouse every other day for five times.

Techniques: Staining, Gene Expression, Microarray

Journal: bioRxiv

Article Title: Tertiary lymphoid structures induced by CXCL13-producing CD4 + T cells increase tumor infiltrating CD8 + T cells and B cells in ovarian cancer

doi: 10.1101/2021.12.01.470493

Figure Lengend Snippet: (A) Fluorescent double staining of CXCL13 (red) and CD4 (green), and CXCL13 (red) and CD8 (white) by RNA ISH in TLS. Images of four representative TLS are shown. (B) Fluorescent double staining of CXCL13 (red) and CD4 (green), and CXCL13 (red) and CD8 (white) by RNA ISH in TIL. The upper and lower pictures are representative TIL images from the same patient. Nuclei are stained with DAPI (blue). Scale bars indicate 100 µm. Co-localization of CXCL13 with CD4 or CD8 is shown in the bar graph as the relative positive ratio quantified using BZ-H4C/hybrid cell count software.

Article Snippet: Mouse recombinant CXCL13 (R&D Systems) treatment was initiated one day after the tumor inoculation and administered intraperitoneally at 1 μg/mouse every other day for five times.

Techniques: Double Staining, Staining, Cell Counting, Software

Journal: bioRxiv

Article Title: Tertiary lymphoid structures induced by CXCL13-producing CD4 + T cells increase tumor infiltrating CD8 + T cells and B cells in ovarian cancer

doi: 10.1101/2021.12.01.470493

Figure Lengend Snippet: (A) Representative images of early TLS. (B) Representative images of follicle-formed TLS. Upper panels show CXCL13 (RNA ISH, Fast RED) and lower panels show FDC (CD21 IHC, DAB). (C) Fluorescence double staining of CXCL13 (red) and CD4 (green), CXCL13 (red) and CD8 (white), and CXCL13 (red) and CD21 (light blue) in representative early TLS and follicle-formed TLS. Nuclei are stained with DAPI (blue). Scale bar indicates 100 µm. Co-localization of CXCL13 with CD4, CD8, or CD21 is shown in the bar graph as the relative positive ratio quantified using BZ-H4C/hybrid cell count software.

Article Snippet: Mouse recombinant CXCL13 (R&D Systems) treatment was initiated one day after the tumor inoculation and administered intraperitoneally at 1 μg/mouse every other day for five times.

Techniques: Fluorescence, Double Staining, Staining, Cell Counting, Software

Journal: bioRxiv

Article Title: Tertiary lymphoid structures induced by CXCL13-producing CD4 + T cells increase tumor infiltrating CD8 + T cells and B cells in ovarian cancer

doi: 10.1101/2021.12.01.470493

Figure Lengend Snippet: (A) Correlation between CXCL13 and TGF-β1 expression in TCGA (n=217) and KOV (n=28). Correlation was determined by Spearman’s correlation test. (B) Human naïve CD4 + and CD8 + T cells from a healthy donor were differentiated by TCR stimulation and TGF-β1 in the presence or absence of a TGF signal inhibitor, SB431542. The proportion of CXCL13 + cells was determined by flow cytometry. Data are shown as the mean ± SEM of four samples. Statistical significance was determined by two-tailed Student’s t -test, * P <0.05, ** P <0.01, *** P <0.001, n.s.: not significant. (C) The concentration of TGF-β1 in conditioned medium obtained from three human ovarian cancer cell lines was measured by ELISA. Data are shown as the mean ± SEM of three samples. (D) Human naïve CD4 + and CD8 + T cells from a healthy donor were differentiated with TCR stimulation and conditioned medium obtained from three human ovarian cancer cell lines in the presence or absence of a TGF signal inhibitor, SB431542. The proportion of CXCL13 + cells was determined by flow cytometry. Data are shown as the mean ± SEM of triplicates. (E) (F) (G) Human naïve CD4 + and CD8 + T cells from a healthy donor were differentiated with TCR stimulation and the indicated cytokines. The proportion of CXCL13 + cells was determined by flow cytometry (E) . The concentration of CXCL13 in the culture supernatant was measured by ELISA (F) . Data are shown as the mean ± SEM of four samples in CD4 and three samples in CD8. Statistical significance was determined by two-tailed Student’s t -test, * P <0.05, ** P < 0.01, *** P < 0.001, **** P <0.0001, n.s.: not significant. Representative dot plots of PD-1 (upper row), CXCR5 (lower row), and intracellular CXCL13 in healthy human naïve CD4 + T cells are shown (G) . a IL-2 Ab indicates anti IL-2 antibody.

Article Snippet: Mouse recombinant CXCL13 (R&D Systems) treatment was initiated one day after the tumor inoculation and administered intraperitoneally at 1 μg/mouse every other day for five times.

Techniques: Expressing, Flow Cytometry, Two Tailed Test, Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: Tertiary lymphoid structures induced by CXCL13-producing CD4 + T cells increase tumor infiltrating CD8 + T cells and B cells in ovarian cancer

doi: 10.1101/2021.12.01.470493

Figure Lengend Snippet: (A) Mouse rCXCL13 was administered intraperitoneally to induce TLS in a mouse ovarian cancer model. Representative H&E images of TLS formed in an omental tumor. The area of TLS per tumor area was compared between the control group and the rCXCL13 treated group (n=7, each). Statistical significance was determined by two-tailed Student’s t -test, * P <0.05. (B) TLS induced by mouse rCXCL13 (H&E) and expression of mouse CXCL13 corresponding to TLS (RNA ISH, Fast RED). (C) CD8 + T cell IHC images (DAB) in the rCXCL13 treated group and control group. Scale bars indicate 100 µm. (D) (E) The effect of rCXCL13 administration on the survival of tumor-bearing mice was compared between immunocompetent mice (D) and immunodeficient mice (E). Analyses were performed using Kaplan-Meier estimates and log-rank tests.

Article Snippet: Mouse recombinant CXCL13 (R&D Systems) treatment was initiated one day after the tumor inoculation and administered intraperitoneally at 1 μg/mouse every other day for five times.

Techniques: Control, Two Tailed Test, Expressing